And you conveniently forgot to add that treatment, compliance and vaccination rates were lowest amongst the patients under 40. 60% of participants were aged 45+ so near 40% of patients were under 40 The statistical significance became unreliable because the study across all the participants became underpowered when they had to include the cohort that were less reliable in conforming to the study. The trial does suggest a large benefit was experienced for those that complied with the rules.
Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-52
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $12.03K | 116.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 109616 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |